Patent ID: 9075072
Filing Date: 2015-07-07
Classification: G01N

Abstract:
1. A method of recognizing the development of an Acute Myocardial Infarction (AMI) process in an individual, wherein said method comprises profiling specific antibody reactivities to a set of antigens comprising at least six antigens selected from a group consisting of Brain-1 oligo-dendrocyte transcription factor, Synaptotagmin 1, Tryptophan hydroxylase peptide 1, Tryptophan hydroxylase peptide 2, BSP (Brain specific protein), myelin associated glycoprotein, Fibronectin, Caspase 3, Myelin-associated metalloproteinase, CD68, Bone morphogenic protein 4 and D4GDI (GDP-dissociation inhibitor), said profiling comprising the steps of: i. obtaining a biological fluid specimen from the individual, said specimen containing a specific antibody repertoire; ii. attaching the set of antigens to a substrate; iii. binding said antibodies of said biological fluid specimen to said set of antigens attached to the substrate, thereby forming bound antibody antigen complexes; iv. analyzing the results obtained, comprising: 1) measuring the bound antibody antigen complexes by scanning the substrate using a measuring device adapted to a utilize a method selected from the group consisting of: Surface Plasmon Resonance (SPR), ellipsometry, laser scanning, light detecting, photon detecting via a photon multiplier, photographing with a digital camera based system or video system, fluorescence detecting, and combination thereof so as to produce a fluorescent image of the substrate; and 2) comparing to control antibody reactivities; wherein an AMI process in said individual is indicated by a change in the antibody complexes compared to control, wherein the change in the antibody complexes is characterized by: increased antibody complexes with at least one antigen selected from Brain-1 oligo-dendrocyte transcription factor, Synaptotagmin 1, Tryptophan hydroxylase peptide 1, Tryptophan hydroxylase peptide 2, BSP, myelin associated glycoprotein, Fibronectin, Myelin-associated metalloproteinase, CD68, Bone morphogenic protein 4 and D4GDI, or decreased antibody complex with Caspase 3.